



MEDIGARD LIMITED
Suite 14, 30 Tedder Avenue, Main Beach QLD 4217 Australia
Telephone +61 7 5578 7822; Fax +61 7 5528 4459
E-mail: office@medigard.com.au www.medigard.com.au
ABN 49 090 003 044

7 December 2017

ASX Announcement

Medigard Limited [ASX: MGZ] (“Medigard” or “the Company”) is pleased to offer eligible shareholders the opportunity to apply for new fully paid ordinary shares in the Company under a Share Purchase Plan (“SPP”) up to a total of approximately 32,700,000 shares, to raise up to approximately \$640,000 (the “**Share Purchase Plan**” or “**SPP**”).

The SPP provides the opportunity for eligible shareholders (being those holders of fully paid shares with an address in the Company’s register of shareholders in Australia or New Zealand as at 7:00pm (AEDT) yesterday, 6 December 2017 (“Record Date”)) to subscribe for up to \$15,000 worth of shares without incurring brokerage or other transaction costs.

The issue price will be \$0.02 (217.62 cents) per share, representing a 17.62% discount to the volume weighted average price (“VWAP”) of shares over the last 5 days on which sales of the Company’s shares were recorded prior to this announcement.

As well as an opportunity to increase their shareholding at a 31% discount to the last traded price, the SPP also offers an opportunity for those shareholders holding less than a marketable parcel of shares (i.e. a holding where the current value is less than \$500) to increase their shareholding to more than a marketable parcel.

An indicative timetable is provided below. The SPP is currently scheduled to close on 22 December 2017. The timetable below is subject to change without notice.

Event	Date
Record Date	7:00pm (AEDT) 6 December 2017
Announcement of SPP	7 December 2017
Dispatch of SPP Offer Document and personalised application form	8 December 2017
Opening Date	11 December 2017
Closing Date	7:00pm (AEDT) 22 December 2017
Allotment of SPP shares (anticipated)	2 January 2018

Funds raised by the SPP will primarily be used:

- to support careful further examination of and potential investment into some next-generation needle product innovations the Company has identified;
- to improve the balance sheet strength in the context of the promising and exciting opportunities that are presently under review; and
- for working capital and to pay costs of the SPP.

Full details of the SPP will be contained in the SPP Offer Document and personalised application form for eligible shareholders which will be dispatched to shareholders. The SPP Offer Document will also be announced to ASX upon dispatch to eligible shareholders. Any eligible shareholder wishing to acquire shares under the SPP will need to make payment by BPAY or complete and return the personalised application form with their cheque payment in accordance with the terms of the SPP offer and the instructions in the application form.



PATRICIA BOERO
(Company Secretary)